A communication from the Executive Office of Health and Human Services (see item 4000-0300 contained in Section 2 of Chapter 28 of the Acts of 2023) submitting its quarterly MassHealth Pharmacy Pipeline Report for January 1, 2024-December 31, 2024

This document is a formal submission of the quarterly MassHealth Pharmacy Pipeline Report for the period from January 1, 2024, to December 31, 2024, rather than a new legislative bill. It details the projected costs for 68 new pharmaceutical products expected to become available for MassHealth members during that year, with an estimated total spend of approximately $24.8 million. The report highlights that the majority of this cost increase is driven by the anticipated use of gene therapies for sickle cell disease. This information fulfills a reporting requirement established in Chapter 28 of the Acts of 2023 and is directed to the relevant state committees overseeing health care financing and Medicaid.